Do You Really Need a QPPVA? Understanding Pharmacovigilance Responsibilities in Australia
Many Australian medicine sponsors are familiar with the concept of a Qualified Person for Pharmacovigilance (QPPV), particularly if they operate internationally. However, there is often confusion around what the role means in the Australian context and how it differs from pharmacovigilance arrangements in other jurisdictions.
Australian sponsors are expected to have a QPPVA as part of their pharmacovigilance system. In addition, sponsors must have an Australian pharmacovigilance contact person (A-PVCP) residing in Australia who can be contacted by the Therapeutic Goods Administration (TGA).
While these requirements may appear straightforward, the real challenge lies in ensuring that the individuals fulfilling these roles have appropriate oversight of the Australian pharmacovigilance system and understand the unique characteristics of the Australian market.
The Role of the QPPVA
The QPPVA is responsible for maintaining oversight of the sponsor's pharmacovigilance system and ensuring that safety obligations are met.
Depending on the organisation, responsibilities may include and not limited to:
Oversight of adverse event management
Monitoring compliance with reporting requirements
Ensuring pharmacovigilance procedures remain current
Supporting audits and inspections
Managing vendor oversight
Advising on safety-related regulatory obligations
The QPPVA should have sufficient authority, access to information, and pharmacovigilance expertise to effectively oversee the system.
However, oversight is not simply an administrative exercise. It requires an understanding of how medicines are used, monitored, and regulated within Australia.
Can the QPPVA Be Located Overseas?
Yes.
The TGA does not require the QPPVA to reside in Australia. Many multinational organisations appoint a regional or global pharmacovigilance lead located overseas to fulfil this role.
However, an overseas-based QPPV must still be able to demonstrate meaningful oversight of the Australian pharmacovigilance system.
This extends beyond understanding reporting timelines or internal procedures.
The QPPV should have an understanding of the Australian regulatory environment and be able to assess safety matters within the Australian context.
This may include:
Familiarity with TGA pharmacovigilance requirements
Understanding Australian adverse event reporting obligations
Knowledge of the sponsor's Australian product portfolio
Awareness of local risk management activities
Understanding the Australian healthcare environment and patient population
Oversight of Australian pharmacovigilance vendors and service providers
For example, safety concerns may be influenced by factors unique to Australia, including patterns of medicine use, access to healthcare services, environmental conditions, or characteristics of the local population.
A sunscreen sponsor operating in Australia faces different safety considerations than one operating exclusively in Europe. Similarly, sponsors of complementary medicines must understand the Australian regulatory framework and consumer usage patterns that may differ significantly from overseas markets.
A QPPV who has little visibility of Australian products, consumers, or regulatory expectations may struggle to provide effective oversight, regardless of their global pharmacovigilance experience.
For this reason, sponsors should ensure that overseas-based QPPVs receive appropriate training on Australian pharmacovigilance requirements and remain actively involved in Australian safety oversight activities.
The Australian Pharmacovigilance Contact
In addition to the QPPV, sponsors must nominate a pharmacovigilance contact person who resides in Australia.
This individual serves as the local point of contact for the TGA and should be available to facilitate communication regarding pharmacovigilance matters.
The Australian contact should be able to:
Respond to regulatory enquiries
Coordinate access to safety information
Facilitate communication between the sponsor and regulator
Support inspection and compliance activities
Importantly, this individual should understand how the sponsor's pharmacovigilance system operates and know where relevant information can be accessed.
Can One Person Perform Both Roles?
Yes.
Many Australian sponsors, particularly small and medium-sized organisations, appoint a single individual to perform both the QPPV role and the Australian pharmacovigilance contact role.
This approach often provides:
Clear accountability
Simplified governance
Faster communication with regulators
Reduced risk of oversight gaps
Provided the individual resides in Australia and possesses the necessary pharmacovigilance expertise, combining the roles can be an effective and practical solution.
For many sponsors, this arrangement also helps ensure that the person responsible for regulatory interactions has direct visibility of day-to-day pharmacovigilance activities.
Common Pitfalls Sponsors Encounter
Assuming Global Oversight Is Sufficient
One of the most common issues is assuming that a global pharmacovigilance structure automatically satisfies Australian requirements.
While global systems can provide a strong framework, sponsors should be able to demonstrate how Australian safety activities are specifically managed and overseen.
The TGA is likely to focus on how the Australian component of the pharmacovigilance system operates, rather than how the global system functions overall.
Assuming Outsourcing Removes Responsibility
Sponsors frequently outsource pharmacovigilance activities to specialist providers.
However, outsourcing does not remove the sponsor's responsibility for compliance.
Sponsors remain accountable for:
Vendor oversight
Reporting compliance
Governance arrangements
Quality management of pharmacovigilance activities
The effectiveness of outsourced arrangements ultimately remains the sponsor's responsibility.
Unclear Ownership of Pharmacovigilance Activities
In smaller organisations, responsibilities are often spread across regulatory affairs, quality, customer service, and medical functions.
Without clear ownership, safety information may be delayed, overlooked, or handled inconsistently.
Sponsors should ensure that pharmacovigilance oversight responsibilities are clearly assigned and documented.
What Does the TGA Expect to See?
Regardless of organisational structure, sponsors should be able to demonstrate:
A designated QPPVA
An Australian-resident pharmacovigilance contact (A-PVCP)
Clearly documented responsibilities
Effective oversight of adverse event management
Appropriate training and governance arrangements
Adequate oversight of outsourced activities
Evidence that the QPPV understands Australian pharmacovigilance requirements and the Australian healthcare environment
The focus is not simply on whether the required roles have been assigned, but whether those individuals can effectively fulfil their responsibilities.
Conclusion
The question is not whether Australian sponsors need a QPPV. The question is whether the sponsor's pharmacovigilance structure provides genuine oversight of medicine safety within the Australian context.
While a QPPV may be located anywhere in the world, they should be able to demonstrate an understanding of Australian pharmacovigilance requirements, Australian patients, Australian healthcare practices, and the specific safety considerations associated with products supplied to the Australian market.
Ultimately, effective pharmacovigilance oversight requires more than a title. It requires knowledge, accountability, and a clear understanding of how medicine safety is managed in the environment where patients actually use the product.
